Nevanac 1mg/ml eye drops suspension - (emc) | 6549
Nevanac 1mg/ml eye drops suspension - Summary of Product Characteristics (SmPC) by Novartis Pharmaceuticals UK Ltd
www.medicines.org.ukNevanac (nepafenac) remains a prescription NSAID eye drop used to reduce postoperative inflammation and, in diabetics, to lower the risk of macular edema after cataract surgery. Here’s the latest, distilled:
- Regulatory status: It is approved in major regions (EMA label materials from 2018 and UK/NHS appraisals show ongoing use for postoperative inflammation and macular edema prevention) [EMA: Nevanac EPAR; UK SmPC]. These sources indicate standard dosing regimens and safety profiles used in adults, with cautions for corneal health and potential adverse events [EMA: Nevanac EPAR][UK SmPC].
- Dosing and duration: Typical regimens involve multiple daily instillations starting around the time of cataract surgery; duration can extend up to 60 days when used to reduce macular edema risk, and shorter courses for general inflammation control, depending on regional labeling and clinician judgment [EMA EPAR; UK SmPC; NHS Wales/AWMSG assessments].
- Safety signals: The most common ocular adverse events include punctate keratitis, corneal epithelium defects, and rare allergic reactions; serious corneal events and epithelial breakdown can necessitate discontinuation and monitoring of corneal health [UK SmPC; EMA PIL/EMC extracts]. Contact lens wearers are advised to avoid during treatment due to benzalkonium chloride content, and hypersensitivity to nepafenac or NSAIDs is a contraindication [EMA EPAR; SmPC].
- Availability and access: Nevanac is typically available by prescription in many countries with national or regional formularies supporting its use for post-cataract inflammation and diabetic macular edema risk; local access may vary by country and updated guidance [EMA EPAR; NHS/Scotland appraisal notes].
If you’d like, I can pull the most current country-specific guidance (e.g., US, UK, EU, or your local health authority) and summarize any recent updates or changes to dosing, duration limits, or safety warnings. I can also provide a patient-friendly quick-reference dosing chart based on the latest official labels.
Would you like country-specific details or a concise dosing checklist for patients?
Citations: EMA Nevanac EPAR and associated product information; UK Medicines EMC/SmPC and NHS appraisal records.[2][3][4]